Resalis Therapeutics
Tackling metabolic disorders with non-coding RNAs
- Employees
- 1–10
- Founded
- 2021
- Website
- resalistherapeutics.com
- Last Round
- Venture RoundOct 2024
- Rounds
- 2
About
Resalis Therapeutics develops non-coding-RNA medicines for obesity and metabolic disease. Its lead program, RES-010, targets microRNA-22, a regulator of lipid metabolism and insulin signaling, to pursue durable weight loss and reductions in hepatic steatosis. The company is advancing the program from preclinical evidence into clinical trials for metabolic disorders.
Summary
Resalis Therapeutics is a Biotech company, founded in 2021. Its most recent funding was a Venture Round in Oct 2024. Investors include Sanofi Ventures and Claris Ventures.
Tech & App Stack
1 technology or app tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Oct 2024
Sign up to see all 2 events
Funding: Series A through Venture Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/resalis-therapeutics"><img src="https://indexed.vc/api/badge/company/resalis-therapeutics" alt="Resalis Therapeutics on Indexed.vc" width="260" height="76" /></a>